close

Mylan to collaborate on biosimilar products

2 min read
article image -

CANONSBURG — Mylan N.V. said Friday it has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals, Inc. to develop, manufacture and commercialize six of Momenta’s current biosimilar candidates, including Momenta’s biosimilar candidate, Orencia.

A biosimilar is a biopharmaceutical drug designed to have active properties similar to one that has previously been licensed.

“Mylan’s long-stated strategy has been to strategically invest in the long-term drivers of our future growth, both through our strong internal focus on R&D and through external collaboration with industry-leading partners,” said Mylan CEO Heather Bresch. “Biosimilars have long been one of these areas of important future growth, both for our company and our industry, given the rapidly growing market for biologic products, the undeniable patient need for more affordable versions of these life-saving medicines, and the attractive competitive landscape for the companies that are able to successfully bring these complex products at scale to the global market.”

Bresch said the collaboration with Momenta, which is highly complementary to Mylan’s partnership with Biocon, “will position us as a definitive world leader in biosimilars, with a broad portfolio of 15 biosimilar/insulin analog generic products in development and the scale required to maximize investment in this area.”

Mylan’s collaboration with Momenta builds upon its existing biologics and insulin analog partnership with Biocon, which includes six biosimilar programs (trastuzumab, pegfilgrastim, adalimumab, bevacizumab, etanercept and filgrastim) and three insulin analogs (glargine, lispro and aspart). Mylan said five of these biosimilar programs have successfully completed Phase I clinical trials, and four of the programs are in active Phase III testing.

CUSTOMER LOGIN

If you have an account and are registered for online access, sign in with your email address and password below.

NEW CUSTOMERS/UNREGISTERED ACCOUNTS

Never been a subscriber and want to subscribe, click the Subscribe button below.

Starting at $3.75/week.

Subscribe Today